lenalidomide

Leah SherwoodMyeloma | November 16, 2022
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Leah SherwoodMyeloma | November 16, 2022
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Leah LawrenceMyeloma | February 3, 2023
However, the three-drug combination improved survival in the relapsed/refractory setting.
Advertisement
Advertisement
Advertisement
Advertisement